Nanogen Expands Intellectual Property Surrounding Technologies for Genetic Analysis

May 02, 2005, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, May 2 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN),
 developer of advanced diagnostic products, announced today that it has been
 issued two patents by the U.S. Patent and Trademark Office for technologies
 related to genetic analysis.  U.S. Patent 6,884,584, "Hybridization and
 Mismatch Discrimination Using Oligonucleotides Conjugated to Minor Groove
 Binders," claims the use of Nanogen's MGB probes on traditional solid phase
 support.  An unrelated patent, U.S. Patent No. 6,887,362, "Dielectrophoretic
 Separation and Immunoassay Methods on Active Electronic Matrix Devices"
 relates to devices and methods for performing active, multi-step molecular and
 biological sample preparation and diagnostic analyses employing immunochemical
 techniques.  Nanogen's growing intellectual property portfolio now includes
 117 U.S. patents.
     The '584 patent for the minor groove binder technology relates to
 conjugates between a minor groove binding molecule and an oligonucleotide,
 which are used as probes to facilitate various analytic and diagnostic
 procedures.  The application covered by this patent utilizes a "capture down"
 approach, where a target nucleic acid, immobilized directly or indirectly to a
 solid support such as glass, is detected with a minor groove binder
 oligonucleotide probe.  Minor groove binder technology is based on a potent
 class of naturally occurring antibiotics that bind to the minor groove of
 double stranded DNA.  When attached to either the 5' or 3' terminus of DNA
 probes, hydrophobic binding of minor groove binder molecules to the minor
 groove stabilizes the DNA duplex formed by these probes hybridizing to their
 complementary targets.  This allows the use of shorter probes with higher
 sensitivity to mismatches.  Nanogen's minor groove binder probe technology
 greatly improves the performance of hybridization-based systems for genetic
 analysis, including the detection of single nucleotide polymorphisms, the
 measurement of DNA and RNA isolates and allows the generation of highly
 sensitive gene expression systems.
     The '362 patent relates to bioparticle separation, bioparticle enrichment
 and electric field-mediated immunochemical detection on active electronic
 matrix devices utilizing electric fields.  The invention relates to devices
 and methods for sample preparation, manipulation, immunoimmobilization and
 immunoassays, all of which can be conducted on one or more active electronic
 chip devices within a single system.  These manipulations are useful in a
 variety of applications, including, for example, detection of pathogenic
 bacteria and biological warfare agents, point-of-care diagnostics, food or
 medical product quality control assays, and other biological assays.
     "These patents further strengthen our position as a technology leader in
 the genetic analysis market," said Howard C. Birndorf, Nanogen's chairman of
 the board and CEO.  "Our minor groove binding technology, which is part of the
 MGB Eclipse(TM) Probe Systems and MGB Eclipse(TM) Detection reagents, provides
 product differentiation and superior performance for our research and clinical
 customers employing widely-used real-time PCR applications for molecular and
 gene-expression analysis."
     About Nanogen, Inc.
     Nanogen's advanced diagnostics provide physicians and patients worldwide
 with sophisticated information to predict, diagnose and treat disease.
 Research and clinical reference labs use the highly accurate and reliable
 NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
 and broad suite of analyte specific reagents to develop diagnostic tests for
 variety of diseases.  Nanogen also offers a broad portfolio of patented
 nucleic acids chemistries and molecular tools that accelerate genomic analysis
 and are compatible with many systems.  The SynX subsidiary offers a line of
 point-of-care diagnostic tests and is building expertise in cardiac related
 health conditions.  Nanogen's ten years of pioneering research involving
 nanotechnology may also have future applications in medical diagnostics,
 biowarfare and other industries.  For additional information please visit
 Nanogen's website at
     Nanogen Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.